Back to Trades
Buy4
Kailera Therapeutics, Inc.
KLRA
Total Value
$134.4M
Net $134.4M bought
Purchases
$134.4M
1 transaction
Company Information
- Company Name
- Kailera Therapeutics, Inc.
- Ticker Symbol
- KLRA
- CIK
- 0002096997
Insider Information
- Role
- Insider
- Location
- BOSTON, MA
Filing Details
- Filing Date
- Apr 20, 2026
- Transaction Date
- Apr 20, 2026
- Accession Number
- 0001193125-26-164417
- Form Type
- 4
- Net Trading Amount
- $134.4M
Non-Derivative Transactions
| Date | Security | Shares | Price | Type | Value |
|---|---|---|---|---|---|
| Apr 20, 2026 | Common Stock | 17,857,143 | — | C | — |
| Apr 20, 2026 | Common Stock | 8,398,438 | $16.00 | Purchase | $134.4M |
Derivative Transactions
| Date | Security | Shares | Exercise Price | Type | Value |
|---|---|---|---|---|---|
| Apr 20, 2026 | Derivative | 17,857,143 | — | C | — |
Footnotes
- (F1)Each share of the Issuer's Series B Preferred Stock automatically converted into shares of the Issuer's Common Stock on a 1:1 basis upon the closing of the Issuer's initial public offering. These securities had no expiration date.
- (F2)Represents securities held directly by BCPE Perseus Investor, LP ("BCPE Perseus").
- (F3)Bain Capital Investors, LLC ("BCI") is the manager of Bain Capital XIV General Partner, LLC ("BCPE Fund XIV GP"), which is the general partner of Bain Capital Fund XIV, L.P. ("BCPE Fund XIV"), which is the managing member of BCPE Perseus Investor GP, LLC ("BCPE Perseus GP"), which is the general partner of BCPE Perseus. As a result, each of BCI, BCPE Fund XIV GP, BCPE Fund XIV and BCPE Perseus GP may be deemed to share voting and dispositive power with respect to the securities held by BCPE Perseus. BCI, BCPE Fund XIV GP, BCPE Fund XIV and BCPE Perseus GP each disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.